ADMA Biologics (NASDAQ:ADMA) Trading Down 8.8% – What’s Next?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price was down 8.8% on Monday . The company traded as low as $16.76 and last traded at $16.93. Approximately 554,779 shares were traded during trading, a decline of 71% from the average daily volume of 1,946,501 shares. The stock had previously closed at $18.56.

Wall Street Analyst Weigh In

ADMA has been the subject of several research reports. Raymond James increased their price objective on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th. HC Wainwright boosted their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th.

ADMA Biologics Stock Down 9.5 %

The stock has a fifty day simple moving average of $19.39 and a two-hundred day simple moving average of $17.15. The firm has a market cap of $3.97 billion, a PE ratio of 60.00 and a beta of 0.76. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period in the prior year, the company posted $0.01 EPS. As a group, sell-side analysts expect that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CFO Brad L. Tade sold 15,000 shares of the firm’s stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total transaction of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Institutional investors have recently modified their holdings of the stock. State Street Corp boosted its holdings in shares of ADMA Biologics by 61.4% during the 3rd quarter. State Street Corp now owns 13,004,993 shares of the biotechnology company’s stock valued at $259,970,000 after acquiring an additional 4,945,063 shares during the last quarter. Lord Abbett & CO. LLC bought a new stake in ADMA Biologics in the 3rd quarter worth approximately $61,858,000. Bank of Montreal Can purchased a new stake in ADMA Biologics during the 2nd quarter valued at $17,886,000. D. E. Shaw & Co. Inc. lifted its holdings in shares of ADMA Biologics by 26.8% during the 2nd quarter. D. E. Shaw & Co. Inc. now owns 6,824,517 shares of the biotechnology company’s stock valued at $76,298,000 after buying an additional 1,442,799 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of ADMA Biologics by 785.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,194,221 shares of the biotechnology company’s stock worth $23,872,000 after buying an additional 1,059,394 shares during the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.